OssDsign (DB:5J6) - Stock Price, News & Analysis

5J6 Stock Overview

Designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally.

About the company

5J6 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 23.91% per year

Risk Analysis

Volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap (€947M)

OssDsign AB (publ) Competitors

Paul Hartmann

DB:PHH2

€713.9m

Bioservo Technologies

MUN:10B

€4.3m

VITA 34

XTRA:V3V

€81.9m

LIMES Schlosskliniken

XTRA:LIK

€102.6m

Price History & Performance

Summary of all time highs, changes and price drops for OssDsign
Historical stock prices
Current Share Price	kr0.83
52 Week High	kr0.91
52 Week Low	kr0.35
Beta	0.81
1 Month Change	1.34%
3 Month Change	5.73%
1 Year Change	105.69%
3 Year Change	6.95%
5 Year Change	n/a
Change since IPO	-42.89%

Recent updates

Shareholder Returns

	5J6	DE Medical Equipment	DE Market
7D	0.6%	0.7%	-0.2%
1Y	105.7%	0.2%	2.4%

Return vs Industry: 5J6 exceeded the German Medical Equipment industry which returned 0.2% over the past year.

Return vs Market: 5J6 exceeded the German Market which returned 2.4% over the past year.

Price Volatility

Is 5J6's price volatile compared to industry and market?
5J6 volatility
5J6 Average Weekly Movement	7.6%
Medical Equipment Industry Average Movement	4.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 5J6 has not had significant price volatility in the past 3 months.

Volatility Over Time: 5J6's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2011	25	Morten Henneveld	www.ossdsign.com

OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. It offers OssDsign Catalyst, a nanosynthetic bone graft used to help stimulate bone growth in spinal fusions. The company was founded in 2011 and is headquartered in Uppsala, Sweden.

OssDsign AB (publ) Fundamentals Summary

How do OssDsign's earnings and revenue compare to its market cap?
5J6 fundamental statistics
Market cap	€84.21m
Earnings (TTM)	-€10.52m
Revenue (TTM)	€10.47m

8.0x

P/S Ratio

-7.9x

P/E Ratio

Is 5J6 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
5J6 income statement (TTM)
Revenue	kr117.72m
Cost of Revenue	kr23.87m
Gross Profit	kr93.85m
Other Expenses	kr212.24m
Earnings	-kr118.39m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 20, 2024

Earnings per share (EPS)	-1.21
Gross Margin	79.72%
Net Profit Margin	-100.57%
Debt/Equity Ratio	0.3%

How did 5J6 perform over the long term?

See historical performance and comparison

5J6 Stock Overview

Rewards

Risk Analysis

OssDsign AB (publ) Competitors

DB:PHH2

€713.9m

MUN:10B

€4.3m

XTRA:V3V

€81.9m

XTRA:LIK

€102.6m

Price History & Performance

Recent News & Updates

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023)

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

Forecast breakeven date moved forward to 2024

Recent updates

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023)

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

Forecast breakeven date moved forward to 2024

Full year 2023 earnings released: kr1.60 loss per share (vs kr1.70 loss in FY 2022)

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Now 22% undervalued

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Forecast breakeven date moved forward to 2024

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

No longer forecast to breakeven

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.30 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.40 loss per share (vs kr0.40 loss in 2Q 2021)

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

First quarter 2022 earnings released: kr0.40 loss per share (vs kr1.10 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.

New Scientific Paper Further Confirms Osteointegration of OssDsign Cranial PSI Implants

First quarter 2021 earnings released: kr1.10 loss per share (vs kr1.00 loss in 1Q 2020)

Anders Svensson Joins OssDsign AB (Publ) as Chief Financial Officer

OssDsign AB (publ), Annual General Meeting, Jun 04, 2021

New 90-day low: €1.35

Full year 2020 earnings released: kr4.40 loss per share (vs kr5.46 loss in FY 2019)

Revenue misses expectations

OssDsign AB (publ) Announces New Clinical Data from 1,055 Cranioplasty Procedures

New 90-day low: €1.36

Chairman of the Board recently bought €26k worth of stock

Svensson's CFO Claes Lindblad Is Leaving the Company

Third quarter 2020 earnings released: kr1.10 loss per share

Revenue misses expectations

OssDsign AB (publ) to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.42